Genmab
GMAB
50.60
-0.75
-1.46%
Genmab
US · GMAB
#860 by market cap
Listed 2019
50.60
-0.75
-1.46%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:56
Recent news
-
Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Cuts Target Price to $56\u5e02\u573a\u8d44\u8baf · 2026/11/13
-
Rating change
H.C. Wainwright Maintains Genmab(GMAB.US) With Buy Rating, Raises Target Price to $70\u5e02\u573a\u8d44\u8baf · 2026/10/29
-
Rating change
H.C. Wainwright Maintains Genmab(GMAB.US) With Buy Rating, Raises Target Price to $50\u5e02\u573a\u8d44\u8baf · 2026/10/7
-
Rating change
H.C. Wainwright Maintains Genmab(GMAB.US) With Buy Rating, Maintains Target Price $50\u5e02\u573a\u8d44\u8baf · 2026/10/26
-
Rating change
Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Raises Target Price to $42\u5e02\u573a\u8d44\u8baf · 2026/10/20
-
Rating change
Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Raises Target Price to $57\u5e02\u573a\u8d44\u8baf · 2026/10/31
-
Rating change
H.C. Wainwright Maintains Genmab(GMAB.US) With Buy Rating, Maintains Target Price $70\u5e02\u573a\u8d44\u8baf · 2026/10/31
-
A Quick Look at Today's Ratings for Genmab(GMAB.US), With a Forecast Between $57 to $70\u5e02\u573a\u8d44\u8baf · 2026/11/7
-
Rating change
TD Cowen Maintains Genmab(GMAB.US) With Buy Rating, Maintains Target Price $43\u5e02\u573a\u8d44\u8baf · 2026/10/6
-
Rating change
Guggenheim Maintains Genmab(GMAB.US) With Buy Rating, Raises Target Price to $58\u5e02\u573a\u8d44\u8baf · 2026/10/7
-
Rating change
Truist Financial Maintains Genmab(GMAB.US) With Buy Rating, Announces Target Price $45\u5e02\u573a\u8d44\u8baf · 2026/10/9
-
Rating change
BofA Securities Maintains Genmab(GMAB.US) With Buy Rating\u5e02\u573a\u8d44\u8baf · 2026/11/3
-
Leerink Partners Maintains Genmab(GMAB.US) With Buy Rating, Raises Target Price to $65\u5e02\u573a\u8d44\u8baf · 2026/10/29
-
Rating change
TD Cowen Maintains Genmab(GMAB.US) With Buy Rating, Raises Target Price to $52\u5e02\u573a\u8d44\u8baf · 2026/10/26
-
Rating change
Truist Financial Maintains Genmab(GMAB.US) With Buy Rating\u5e02\u573a\u8d44\u8baf · 2026/10/5
-
Rating change
William Blair Maintains Genmab(GMAB.US) With Buy Rating\u5e02\u573a\u8d44\u8baf · 2026/10/5
-
US Stock Market Alert | Genmab (GMAB.US) Surges Nearly 26% Intraday, Hitting an All-Time HighZhitong Finance · 2026/10/28
-
Leerink Partners Maintains Genmab(GMAB.US) With Buy Rating, Raises Target Price to $60\u5e02\u573a\u8d44\u8baf · 2026/10/28
-
Rating change
Guggenheim Maintains Genmab(GMAB.US) With Buy Rating, Raises Target Price to $54\u5e02\u573a\u8d44\u8baf · 2026/10/5
-
Rating change
A Quick Look at Today's Ratings for Genmab(GMAB.US), With a Forecast Between $65 to $80\u5e02\u573a\u8d44\u8baf · 2026/10/30
-
Rating change
H.C. Wainwright Maintains Genmab(GMAB.US) With Buy Rating, Maintains Target Price $40\u5e02\u573a\u8d44\u8baf · 2026/9/14
-
Rating change
A Quick Look at Today's Ratings for Genmab(GMAB.US), With a Forecast Between $40 to $40\u5e02\u573a\u8d44\u8baf · 2026/6/30
-
H.C. Wainwright Maintains Genmab(GMAB.US) With Buy Rating, Maintains Target Price $50\u5e02\u573a\u8d44\u8baf · 2026/10/19
-
Rating change
Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Maintains Target Price $33\u5e02\u573a\u8d44\u8baf · 2026/7/23
-
Rating change
Analysts Offer Insights on Healthcare Companies: Genmab (GMAB) and Hinge Health, Inc. Class A (HNGE)TipRanks · 2026/6/30
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 19:56:12 · For reference only, not investment advice and not tailored to your situation.
Genmab discussion 0 comments